Table 3. Adverse events considered related to study treatment (CDX-1401, resiquimod, and/or poly-ICLC).

Table includes all adverse events reported with a possible, probable, or definite relationship to any of the study treatments, occurring in more than one patient. No grade 3, 4, or 5 events have been reported as potentially related to study treatment.

	CDX-1401plus topical resiquimod (cohorts 1–3; n = 23), n (%)	CDX-1401 plus poly-ICLC (cohort 4; n = 7), n (%)	CDX-1401 plus subcutaneous resiquimod (cohort 5; n = 7), n (%)	CDX-1401 plus poly-ICLC and subcutaneous resiquimod (cohort 6; n = 8), n (%)
Administration site reaction	18 (78)	5 (71)	5 (71)	7 (88)
Fatigue	5 (22)	3 (43)	2 (29)	1 (13)
Nausea	2 (9)	0 (0)	0 (0)	2 (25)
Chills	1 (4)	1 (14)	0 (0)	2 (25)
Influenza-like illness	2 (9)	1 (14)	0 (0)	0 (0)
Decreased appetite	3 (13)	0 (0)	0 (0)	0 (0)
Arthralgia	2 (9)	0 (0)	0 (0)	1 (13)
Myalgia	0 (0)	0 (0)	2 (29)	1 (13)
Pyrexia	1 (4)	1 (14)	0 (0)	0 (0)
Hemoglobin decreased	2 (9)	0 (0)	0 (0)	0 (0)
Dizziness	1 (4)	0 (0)	0 (0)	1 (13)